Polaryx Therapeutics, Inc. PLYX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.75M | 2.50M | 1.56M | 1.58M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.22M | 4.73M | 7.82M | 7.63M | -- |
| Operating Income | -5.22M | -4.73M | -7.82M | -7.63M | -- |
| Income Before Tax | -6.85M | -6.48M | -8.99M | -8.21M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.85 | -6.48 | -8.99 | -8.21 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.85M | -6.48M | -8.99M | -8.21M | -- |
| EBIT | -5.22M | -4.73M | -7.82M | -7.63M | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.15 | -0.14 | -0.20 | -0.19 | -- |
| Normalized Basic EPS | -0.09 | -0.09 | -0.12 | -0.12 | -- |
| EPS Diluted | -0.15 | -0.14 | -0.20 | -0.19 | -- |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.12 | -0.12 | -- |
| Average Basic Shares Outstanding | 188.16M | 184.55M | 181.67M | 174.06M | -- |
| Average Diluted Shares Outstanding | 188.16M | 184.55M | 181.67M | 174.06M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |